Mark William Lowdell - 01 Dec 2025 Form 4 Insider Report for Inmune Bio, Inc. (INMB)

Reporting relationship: Chief Scientific Officer
Issuer ticker: INMB
Reported as of: 01 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Dec 2025, 16:43:26 UTC
Prior SEC filing: 18 Nov 2025
Next SEC filing: 07 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark William Lowdell

Key filing fact

Mark William Lowdell filed Form 4 for Inmune Bio, Inc. (INMB) on 02 Dec 2025.

Key facts

This page summarizes Mark William Lowdell's Form 4 filing for Inmune Bio, Inc. (INMB).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Dec 2025, 16:43.

Change

Previous filing in this sequence was filed on 18 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001767037 Primary reporting owner

Lowdell Mark William

Relationship: Chief Scientific Officer
Address: C/O INMUNE BIO INC., 225 NE MIZNER BLVD., SUITE 640, BOCA RATON
Signature: /s/ Mark William Lowdell
Signature date: 02 Dec 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INMB transaction Derivative

Option (right to buy)

Award

Transaction value: $0
Shares: +600,000
Change %
Price: $0.000000
Shares after: 600,000
Date: 01 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 600,000
Exercise price: $1.48
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Granted pursuant to the Issuer's Second Amended and Restated 2021 Stock Incentive Plan. One-fourth (1/4) of the option will vest 12 months from the date of grant and thereafter the remaining unvested option will become vested and exercisable pro rata on a monthly basis over three (3) years (1/36 per month) until the option is 100% vested which shall occur on the four-year anniversary of the date of grant.